China Union Holdings has invested in the clinical services provider, which was formed by Joinn Laboratories last year and which will put the cash into expanding manufacturing capacity.
Joinn Biologics, a US-based offshoot of China-headquartered preclinical services provider Joinn Laboratories, has closed a $60m series A round that included real estate developer China Union Holdings, PEdaily reported today.
Private equity firm Huagai Capital led the round, which also featured Suzhou Xiangtang Venture Capital and Chaosheng Capital, while China Union invested through Hong Kong Hualian Holdings, a chemicals, textiles and petrochemicals-focused subsidiary.
Formed in early 2018, Joinn Biologics offers contract development and production services for pharmaceutical developers, covering areas…
